In conclusion, our study provides the first clinical evidence that distinctive subpopulations of Tbet+ T-cells influence the risk of infection, SPM and death in the setting of initial chemoimmunotherapy for CLL. Here, TBX21 is linked to B-cell chronic lymphocytic leukemia.